Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications

Author(s): L. S. Chin, J. A. Olzmann, L. Li

Journal Name: Current Medicinal Chemistry

Volume 15 , Issue 1 , 2008

Become EABM
Become Reviewer
Call for Editor


Accumulation of misfolded proteins in proteinaceous inclusions is a prominent pathological feature common to many agerelated neurodegenerative diseases, including Parkinsons disease, Alzheimers disease, Huntingtons disease, and amyotrophic lateral sclerosis. In cultured cells, when the production of misfolded proteins exceeds the capacity of the chaperone refolding system and the ubiquitin-proteasome degradation pathway, misfolded proteins are actively transported to a cytoplasmic juxtanuclear structure called an aggresome. Aggresome formation is recognized as a cytoprotective response serving to sequester potentially toxic misfolded proteins and facilitate their clearance by autophagy. Recent evidence indicates that aggresome formation is mediated by dynein/dynactin-mediated microtubule- based transport of misfolded proteins to the centrosome and involves several regulators, including histone deacetylase 6, E3 ubiquitin-protein ligase parkin, deubiquitinating enzyme ataxin-3, and ubiquilin-1. Characterization of the molecular mechanisms underlying aggresome formation and its regulation has begun to provide promising therapeutic targets that may be relevant to neurodegenerative diseases. In this review, we provide an overview of the molecular machinery controlling aggresome formation and discuss potential useful compounds and intervention strategies for preventing or reducing the cytotoxicity of misfolded and aggregated proteins.

Keywords: Neurodegenerative diseases, aggresome, HDAC6, parkin, ataxin-3, ubiquilin-1, inclusion body, protein misfolding

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [47 - 60]
Pages: 14
DOI: 10.2174/092986708783330692

Article Metrics

PDF: 127